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Immunoglobulin A (IgA) nephropathy is the most common form greater degree of proteinuria and trend to graft loss compared of glomerulonephritis worldwide and is a frequent cause of endto the nonrecurrent group. [3] To this, the blockade of the reninstage renal disease in Asian and Caucasian populations. [1] angiotensin system-which is generally accepted being Although transplantation represents the optimal form of renal renoprotective in proteinuric nephropathies [4] replacement therapy, recurrence of IgA nephropathy has been relevance in transplant recipients with chronic graft detected in up to 60% of the graft recipients within 10 years dysfunction due to recurrent IgA nephropathy, as recently posttransplant and ultimately may result in graft loss. [2] Given documented by retrospective observations. [5] In the present the increasing imbalance between organ demand and availability, work the authors did not mention the use of angiotensin a better characterization of all factors that may impact longconverting enzyme inhibitors and/or angiotensin II receptor term graft outcome is mandatory. This may be of particular blockers. It would be interesting for future investigations, to relevance for developing countries, where resources to support prospectively study whether the use of these agents might organ transplant programs are scanty.
impact long-term graft outcome in patients experiencing or not experience recurrence of the disease. In this issue of the journal Chacko et al [3] attempted to determine the long-term graft outcome in Indian renal transplant recipients whose native kidney disease was IgA 
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in a reference group including patients without IgA nephropathy, suggesting that this disease does not represent a contraindication for kidney transplantation despite a high recurrence of the disease. Of note, the five-year renal allograft survival was eventually better in patients with primary IgA nephropathy (90%) compared to other primary diseases (79%), whereas this trend was reversed at 10 years posttransplant (49% vs. 73%). These results seem to support the recently proposed hypothesis that in patients with this disease, the development of alloreactive anti-HLA IgA antibodies may block the deleterious effect of IgG and IgM antibodies on the graft in the short term, whereas other factors contributing to graft loss, including recurrent disease, may become more relevant on longterm follow-up.
